About Recordati
Recordati is a publicly listed company based in Milan (Italy) founded in 1926, and was acquired by CVC in July 2017. Intergrated pharma focused on development, manufacturing and marketing of drugs. Recordati has completed 6 acquisitions, including EUSA Pharma, Italchimici and Laboratorios Casen Fleet. Its website recordati.com draws about 55 thousand monthly visits. Recordati offers products and services including Specialty and Primary Care Medicines, Rare Diseases Medicines, and Chemical Products. Its focus areas include Diversified Pharmaceuticals. Its legal entity is Opalia s.r.o.
Company details
Recordati was founded in 1926 in Milan, Italy, as a company in the pharmaceutical sector. Research, development, manufacturing, and marketing of pharmaceuticals and pharmaceutical chemicals are conducted. Two active pharmaceutical ingredient manufacturing sites are maintained. Lead candidates include REC 0551, in phase 2 for retinopathy of prematurity, and LYNOVEX, in phase 2 for acute infectious exacerbations in cystic fibrosis. REAGILA has been introduced for schizophrenia treatment.
- Headquarters Milan, Italy
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website recordati.com
- Social LinkedIn
- Acquired by CVC (Jul 2017)
- Legal Name Recordati Industria Chimica E Farmaceutica S.P.A.
- Annual Revenue$3.08 B (USD)11.82as on Dec 31, 2025
- Net Profit$521.25 M (USD)6.51as on Dec 31, 2025
- EBITDA$1.09 B (USD)12.01as on Dec 31, 2025
- Investors
- Investments & AcquisitionsEUSA Pharma
& 5 more
- Acquired byCVC
(Jul 2017)
Products & Services of Recordati
Recordati offers a comprehensive portfolio of products and services, including Specialty and Primary Care Medicines, Rare Diseases Medicines, and Chemical Products.
Medicines for common diseases and primary care treatments.
Treatments targeting rare medical conditions globally.
Industrial chemicals used in pharmaceutical manufacturing.
Investors in Recordati
Recordati has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include CVC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Mezzanine financing and equity investments are provided by CVC. | 1981 | cvc.com | New York, United States |
Investor details for Recordati
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Recordati
7 people are tracked at Recordati (4 in leadership, 3 in team).
| Name | Role | Group |
|---|---|---|
Jean-Claude Roche | General Manager | Leadership |
Michael Waters | President & GM, US | Leadership |
Corrado Castellucci | VP, Director Orphan Drugs | Leadership |
Jeroen Commissaris | VP Of Commercial - US Oncology | Leadership |
Emma Rogerson | National Multichannel Account Manager | Team |
Jean Burgee | MSAT Project Manager | Team |
Hayyan Almohtaseb | Key Account Manager/ods | Team |
Complete people profiles for Recordati
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Recordati
Recordati is a publicly listed company on the MIL with ticker symbol REC in Italy, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Jun 1994
- Listed onEuronext: REC
- Listed entityRecordati Industria Chimica e Farmaceutica S.p.A.
- Exchange sectorHealth technology
- ISINIT0003828271
- Share price52.95 EUR · 2026-10-14
- Market capitalisation10,927,019,119.00 EUR
- Price to earnings22.2
- EPS (diluted, trailing year)2.38 EUR
- Dividend yield2.53%
- Volume (last session)523
Financials of Recordati
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 2.62B EUR | 443.6M EUR | 926.2M EUR |
| 2024 | 2.34B EUR | 416.5M EUR | 826.9M EUR |
| 2023 | 2.08B EUR | 389.2M EUR | 708.4M EUR |
| 2022 | 1.85B EUR | 312.3M EUR | 620.1M EUR |
| 2021 | 1.58B EUR | 386.0M EUR | 602.9M EUR |
Detailed financial statements for Recordati
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Recordati
Recordati has strategically engaged in corporate development activities, having acquired 6 companies. Notable acquisitions include EUSA Pharma, Italchimici and Laboratorios Casen Fleet.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developer and commercializer of pharmaceutical medicines | eusapharma.com | Hemel Hempstead, United Kingdom | 2006 | Dec 2021 | $845M | |
Managed IT services are provided for small and large businesses. | naturalpoint.it | Milan, Italy | 1993 | Jun 2018 | •••• | |
Manufacturer of all-terrain pushchairs and electric cargo bikes | profarma.ch | Baar, Switzerland | 2015 | Jul 2016 | $16.22M | |
Manufacturer of generic drugs and branded food supplements | italchimici.com | Milan, Italy | 1962 | May 2016 | $144.6M | |
Pharmaceuticals for diseases including gastroenterology and women's health are developed. | casenfleet.com | Utebo, Spain | 2022 | Sep 2013 | $122.55M | |
Generic drugs are manufactured by OPALIA Pharma in Tunisia. | opaliapharma.com.tn | Ariana, Tunisia | 1988 | Jul 2013 | $48.5M |
Complete acquisition details for Recordati
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Recordati
9 dated milestones of Recordati across 95 years, from founding to its latest funding, stage changes and deals.
- Founded Recordati is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires OPALIA Pharma.
- Acquisition Acquires Laboratorios Casen Fleet.
- Acquisition Acquires Italchimici.
- Acquisition Acquires Pro Farma.
- Exit Acquired by CVC.
- Acquisition Acquires Natural Point.
- Acquisition Acquires EUSA Pharma.
Web traffic of Recordati
The website of Recordati (recordati.com) receives about 54.8K visits a month and ranks #770,474 among all websites worldwide, #905 in Biotechnology and Pharmaceuticals.
- Monthly visits54.8K
▲ 108.6% vs previous month
- Unique visitors11.5K
per month
- Global rank#770,474
among all websites
- Category rank#905
Health · Biotechnology and Pharmaceuticals
- Bounce rate42%
- Pages per visit4.7
- Average visit33 sec
- DevicesDesktop 35% · Mobile 65%
Websites whose visitors overlap most with Recordati. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| theravance.com | 100% | 4.4K | #4,418,406 | View details | |
| affymax.com | 100% | View details | |||
| almirall.com | 100% | 36.1K | #950,614 | View details | |
| genoptix.com | 100% | View details | |||
| endo.com | 100% | 10K | #2,323,439 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 25 similar websites and full traffic analytics for Recordati
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 25 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Recordati
Complete news archive for Recordati
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Recordati
Recordati was founded in 1926.
Recordati is headquartered in Milan, Italy. It is registered at Milan, Lombardy, Italy.
Annual revenue of Recordati is $3.08B as on Dec 31, 2025.
Recordati was founded in 1926 in Milan, Italy, as a company in the pharmaceutical sector. Research, development, manufacturing, and marketing of pharmaceuticals and pharmaceutical chemicals are conducted. Two active pharmaceutical ingredient manufacturing sites are maintained. Lead candidates include REC 0551, in phase 2 for retinopathy of prematurity, and LYNOVEX, in phase 2 for acute infectious exacerbations in cystic fibrosis. REAGILA has been introduced for schizophrenia treatment.
Recordati offers Specialty and Primary Care Medicines, Rare Diseases Medicines, and Chemical Products.
Yes, Recordati is publicly traded on MIL under the ticker symbol REC.
Recordati has made 6 acquisitions, including EUSA Pharma, Italchimici, and Laboratorios Casen Fleet.
Recordati has 1 investor. Key investors include CVC.
Recordati operates through Opalia S.R.O..
Yes. Recordati was acquired by CVC in July 2017.